Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | PTAFR | P25105 | 8/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20777203 | 1.00 | NAMPT (0.51) | NAMPTPTAFRF10PRSS1RAB9A | |
| SCHEMBL20777174 | 0.87 | GPR132 (0.51) | NAMPTPTAFRTBXAS1CTSLCTSS | |
| SCHEMBL22802207 | 0.87 | GPR132 (0.51) | NAMPTPTAFRTBXAS1CTSLCTSS | |
| SCHEMBL20777191 | 0.83 | F10 (0.64) | NAMPTF10PRSS1RAB9ACTSL | |
| SCHEMBL20777192 | 0.83 | F10 (0.64) | NAMPTF10PRSS1RAB9ACTSL | |
| SCHEMBL22802198 | 0.78 | NAMPT (0.42) | NAMPTPTAFRTBXAS1CNR1CNR2 | |
| SCHEMBL22822786 | 0.76 | NPC1 (0.48) | F10PRSS1RAB9ACTSLCNR1 | |
| SCHEMBL20777169 | 0.76 | CTSL (0.49) | RAB9ACTSLCTSSCNR1CNR2 | |
| SCHEMBL15162082 | 0.74 | HDAC8 (0.56) | PTAFRRAB9ATBXAS1CNR1CNR2 | |
| SCHEMBL22802205 | 0.74 | NAMPT (0.41) | NAMPTPTAFRTBXAS1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371406-B2 | Dual acting FKBP12 and FKBP52 inhibitors | PLEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12065407-B2 | Dual acting FKBP12 and FKBP52 inhibitors | PLEX PHARMACEUTICALS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | NAMPT 2597/4885PTAFR 2518/4885F10 3682/4885 |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | NAMPT 2597/4885PTAFR 2518/4885F10 3682/4885 |
| US-12065407-B2 | Dual acting FKBP12 and FKBP52 inhibitors | FKBP2, FKBP1B, FKBP1A | NAMPT 2597/4885PTAFR 2518/4885F10 3682/4885 |
| US-12371406-B2 | Dual acting FKBP12 and FKBP52 inhibitors | FKBP2, FKBP1B, FKBP1A | NAMPT 2597/4885PTAFR 2518/4885F10 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.